ArticleNorthern clinics of Istanbul2025
Liver fibrosis scores can also be used as a marker of cardiovascular risk in non-alcoholic fatty liver disease.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to evaluate the relationship between Atherogenic Plasma Index (API), a cardiovascular event risk marker, and hepatic fibrosis level in non-alcoholic fatty liver disease (NAFLD) patients.
methods129 people over the age of 18 with NAFLD were included in the study. Fasting blood glucose (FBG), HOMA-IR, HbA1C, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), albumin, triglyceride (TG), total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), nonHDL-cholesterol (nonHDL-C), direct bilirubin, TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios were calculated. NAFLD fibrosis score (NFS), FIB-4, APRI scores were determinated. It was classified as low, high and intermediate. The API was calculated and its relationship with the level of hepatic fibrosis was evaluated.
resultsThe API level in the high group of NFS is higher than that in the low group. Similarly, the API level in the high group of FIB-4 is higher than that in the low group. The API in the low group of APRI are lower than the ID group. There is a positive correlation between API and NFS, FIB-4, APRI scores in all NAFLD subjects. There is a positive correlation between API and NFS, FIB-4, APRI scores in all NAFLD subjects in the study.
conclusionIn this study, we found that there was a relationship between FIB-4, NFS, APRI scores, API and dyslipidemia in people with NAFLD, and that as the level of fibrosis increased, the risk of cardiovascular event also increased. Liver fibrosis scores can also be used as cardiovascular risk markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.